Home
About
Overview
Sharing Data
ORCID
Help
History (1)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Apoptosis
beta Catenin
Cell Proliferation
Cell Survival
Drug Resistance, Neoplasm
Enzyme Activators
Fingolimod Hydrochloride
Fusion Proteins, bcr-abl
Hematopoietic Stem Cells
Humans
Janus Kinase 2
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mice
Mice, Transgenic
Neoplastic Stem Cells
Propylene Glycols
Protein Kinase Inhibitors
Protein Phosphatase 2
Sphingosine
Wnt Signaling Pathway
Xenograft Model Antitumor Assays
authors with profiles
Besim Ogretmen